Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005023674 | SCV005660584 | uncertain significance | Congenital afibrinogenemia; Familial dysfibrinogenemia | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004747930 | SCV005348651 | likely pathogenic | FGB-related disorder | 2024-05-23 | no assertion criteria provided | clinical testing | The FGB c.221G>T variant is predicted to result in the amino acid substitution p.Arg74Leu. This variant has been reported in the heterozygous state in an individual with dysfibrinogenemia (Shlebak et al 2017. PubMed ID: 27812779). Alternate substitutions of this amino acid residue (p.Arg74Gly and p.Arg74Cys) have also been reported in individuals with dysfibrinogenemia (reported as Arg44Gly in Würtinger et al. 2015. PubMed ID: 26540126; reported as Arg44Cys in Koopman et al. 1992. PubMed ID: 1565641). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as likely pathogenic. |